✦ LIBER ✦

Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting

✍ Scribed by Edgar Faber; David Friedecký; Kateřina Mičová; Šárka Rožmanová; Martina Divoká; Marie Jarošová; Karel Indrák; Tomáš Adam

Book ID: 113027926
Publisher: Springer
Year: 2012
Tongue: English
Weight: 227 KB
Volume: 91
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-011-1394-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cytogenetic and molecular responses to s

Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels

✍ Donna L. Forrest; Shannon Trainor; Ryan R. Brinkman; Michael J. Barnett; Donna E 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Trough imatinib plasma levels are associ

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

✍ Picard, S.; Titier, K.; Etienne, G.; Teilhet, E.; Ducint, D.; Bernard, M.-A.; La 📂 Article 📅 2006 🏛 American Society of Hematology 🌐 English ⚖ 81 KB

XPC genetic polymorphisms correlate with

XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia

✍ Vicent M. Guillem; Francisco Cervantes; Jesús Martínez; Alberto Alvarez-Larrán; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Trough plasma imatinib levels are correl

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia

✍ Sohn, Sang Kyun; Oh, Suk Joong; Kim, Byung Soo; Ryoo, Hun Mo; Chung, Joo Seop; J 📂 Article 📅 2011 🏛 Informa plc 🌐 English ⚖ 250 KB

Imatinib dose escalation in two patients

Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma levels and major molecular response

✍ Edgar Faber; David Friedecký; Kateřina Mičová; Martina Divoká; Beata Katrincsáko 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 236 KB

Mechanisms of genesis of variant translo

Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy

✍ Steven Richebourg; Virginie Eclache; Christine Perot; Marie-France Portnoi; Jacq 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 674 KB